Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LEXICON PHARMACEUTICALS, INC. (LXRX)

Lexicon Q3 revenue falls to $11.3 million as net loss widens to $14.0 million

Negative Impact 3 of 5 earnings Written later

Lexicon Pharmaceuticals reported third-quarter 2026 revenue of $11.3 million, down from $14.2 million a year earlier, and a net loss of $14.0 million, up from $12.8 million. The company completed enrollment in its Phase 3 SONATA-HCM study and expects topline results in the first quarter of 2027.

Key points

  • Total revenues were $11.3 million, including $10.0 million of development milestone revenue from Novo, versus $14.2 million in the third quarter of 2025.
  • Net loss was $14.0 million, or $0.03 per share, compared with $12.8 million, or $0.04 per share, a year earlier.
  • Cash and investments were $183.2 million at September 30, 2026, and SONATA-HCM enrolled 542 patients.

The filing

CompanyLEXICON PHARMACEUTICALS, INC. (LXRX)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:03 AM ET
Accession number0001062822-26-000124

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.